Sensus Healthcare prices $11m IPO

Sensus Healthcare (NSDQ:SRTSU) priced an $11 million initial public offering yesterday, saying it plans to float 2 million shares at $5.50 apiece starting today. Boca Raton, Fla.-based Sensus said the offering, expected to close June 8, also includes a 300,000-unit over-allotment option for the IPO’s underwriters. Each share consists of a unit of stock and a 3-year warrant with an exercise price of $6.75. The offering units are slated to split by July 25, with the stock shares trading on the NASDAQ exchange under the “SRTS” symbol and the warrants under the “SRTSW” symbol. Sensus makes low-energy photon X-ray systems for treating non-melanoma skin cancers, including basal cell and squamous cell carcinomas, and keloids. The company said March 9 that it planned to float more than 1.8 million shares at $10 to $12 apiece, working out to a low-end raise of $18.2 million and a high end of $21.8 million. Later that month, Sensus postponed the IPO. Last month, Sensus scaled back, saying it planned to offer 1.75 million shares at $6.25 apiece, for gross proceeds of $10.9 million. The SRT-100 system has U.S. 510(k) clearance, CE Mark approval in the European Union and approvals from the China Food &Drug Administration and Health Canada; Sensus claims more than 200 installed devices in 11 countries. The company had planned to put $3 million of the IPO proceeds toward hiring new sales reps and a director of marketing, a...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Funding Roundup Initial Public Offering (IPO) Radiosurgery Wall Street Beat Sensus Healthcare LLC Source Type: news

Related Links:

Authors: Yang X, Wang H, Xie E, Tang B, Mu Q, Song Z, Chen J, Wang F, Min J PMID: 32632529 [PubMed - as supplied by publisher]
Source: Protein and Cell - Category: Cytology Tags: Protein Cell Source Type: research
Publication date: Available online 7 July 2020Source: Computational and Structural Biotechnology JournalAuthor(s): Shicai Liu, Jian Wu, Qiang Xia, Hongde Liu, Weiwei Li, Xinyi Xia, Jinke Wang
Source: Computational and Structural Biotechnology Journal - Category: Biotechnology Source Type: research
Publication date: Available online 8 July 2020Source: Journal of Molecular Graphics and ModellingAuthor(s): Reza Maleki, Azadeh Khoshoei, Ebrahim Ghasemy, Alimorad Rashidi
Source: Journal of Molecular Graphics and Modelling - Category: Molecular Biology Source Type: research
Publication date: Available online 8 July 2020Source: Biochimica et Biophysica Acta (BBA) - Molecular Basis of DiseaseAuthor(s): Andreia Pereira-Nunes, Susana Simões-Sousa, Céline Pinheiro, Vera Miranda-Gonçalves, Sara Granja, Fátima Baltazar
Source: Biochimica et Biophysica Acta (BBA) Molecular Basis of Disease - Category: Molecular Biology Source Type: research
AbstractDue to its metabolismvia the serotonin and kynurenine pathways, tryptophan plays a key role in multiple disease processes including cancer. Imaging tryptophan uptake and metabolismin vivo can be achieved with tryptophan derivative positron emission tomography (PET) radiotracers. While human studies with such tracers have been confined to C-11-labeled compounds, preclinical development of F-18-labeled tryptophan-based radiotracers has surged in recent years. We performed a systematic review of studies reporting on such F-18-labeled tryptophan tracers to summarize and compare their biological characteristics and thei...
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research
AbstractPurposeThe early and accurate diagnosis of locoregional recurrence or metastasis in prostate cancer (PC) has a significant impact on treatment options. Prostatic-specific membrane antigen (PSMA) positron emission tomography (PET)/x-ray computed tomograph (CT) imaging has recently been introduced as a novel procedure in managing PC. The aim of this study was to evaluate the efficacy of [68Ga]PSMA PET/CT in managing PC patients and to compare the detection rate of PET/CT and bone scans (BSs) in detecting bone metastasis.ProceduresWe evaluated 415 patients with PC who underwent [68Ga]PSMA PET/CT between March 2015 and...
Source: Molecular Imaging and Biology - Category: Molecular Biology Source Type: research
Dalton Trans., 2020, Accepted Manuscript DOI: 10.1039/D0DT02064H, PaperPengju Feng, Wei Huang, Zhen Chen, Liyuan Hou, Tianfeng Chen, Yiqun Li Effective design of metal complexes to manipulate its lipid-water distribution coefficient is an appealing strategy in improving its cellular penetration and treatment efficacy. Here, we conveniently synthesized three iridium (Ir)... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Dalton Trans. latest articles - Category: Chemistry Authors: Source Type: research
Superficial radiation therapy device developer Sensus Healthcare (NSDQ:SRTSU) today released plans for a global expansion, including new distribution agreements in China, Germany, Mexico, Cuba and Costa Rica. Sensus makes low-energy photon X-ray systems for treating non-melanoma skin cancers, including basal cell and squamous cell carcinomas, and keloids. The Boca Raton, Fla.-based company refers to the technology as superficial radiation therapy, and claims that the tech has been sued to “effectively and safely treat oncological and non-oncological skin conditions.” “Following our new partnersh...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Distribution Oncology Sensus Healthcare LLC Source Type: news
Sensus Healthcare is a medical device company that focuses on providing non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids utilizing superficial radiation technology (SRT). Their proprietary, FDA-cleared SRT technology...
Source: Medgadget - Category: Medical Devices Authors: Tags: Dermatology Exclusive Oncology Source Type: blogs
Sensus Healthcare (NSDQ:SRTSU) said today it closed its initial public offering, raising $11 million through the sale of 2.3 million units at $5.50 each. The offering included a fully-exercised underwriters option of an additional 300,000 units at the IPO price, Sensus said. Each share consists of a unit of stock and a 3-year warrant with an exercise price of $6.75. The offering units are slated to split by July 25, with the stock shares trading on the NASDAQ exchange under the “SRTS” symbol and the warrants under the “SRTSW” symbol. Sensus makes low-energy photon X-ray systems for treating non...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News Funding Roundup Initial Public Offering (IPO) Radiosurgery Sensus Healthcare LLC Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Funding | Health | Keloids | Marketing | Medical Devices | Melanoma | Nonmelanoma Skin Cancer | Skin | Skin Cancer | Sports Medicine | Squamous Cell Carcinoma